MIAN
RGLS

Mariner Independent Advisor Network’s Regulus Therapeutics RGLS Stock Holding History

Mariner Independent Advisor Network’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-7,480
Closed -$61K – 517
2021
Q2 		$61K Buy
+7,480
New +$83.5K ﹤0.01% 505

Other funds holding RGLS

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
ACM
Asymmetry Capital Management San Francisco, California $188M AUM 44.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Mariner Independent Advisor Network's RGLS Position: Q3 2021 in Review

Mariner Independent Advisor Network sold out of Regulus Therapeutics (RGLS) in Q3 2021, closing a stake of 7,480 shares — an estimated $61K sold.

Mariner Independent Advisor Network first reported a position in RGLS in Q2 2021 and held it in 1 quarter. The position peaked at $61K in Q2 2021. 41 funds tracked by Wall St. Rank hold RGLS as of Q3 2021.

  • Mariner Independent Advisor Network reported no remaining Regulus Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Mariner Independent Advisor Network sold 7,480 Regulus Therapeutics shares in Q3 2021, an estimated $61K.
  • Mariner Independent Advisor Network first reported a position in Regulus Therapeutics in Q2 2021 and held it in 1 quarter.
  • Mariner Independent Advisor Network's Regulus Therapeutics position peaked at $61K in Q2 2021.
  • 41 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2021.

Based on Mariner Independent Advisor Network's 13F filing for Q3 2021, filed 17 Nov 2021.